Which drug wins? new study takes on frontal fibrosing alopecia
NCT ID NCT07190534
First seen Sep 30, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study compares two medicines, hydroxychloroquine and methotrexate, to see which works better for frontal fibrosing alopecia (FFA), a scarring hair loss that mainly affects women. About 50 adults with FFA who choose one of these treatments will be followed for up to 48 weeks. The goal is to measure how well each drug reduces disease activity and improves quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTAL FIBROSING ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Erasmus MC University Medical Center
Rotterdam, South Holland, 3015GD, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.